Breaking News

SwiftScale Manufactures COVID-19 Antibody Candidate

Uses rapid biologics manufacturing technology to accelerate development of treatments.

By: Contract Pharma

Contract Pharma Staff

SwiftScale Biologics has successfully manufactured a COVID-19 neutralizing antibody candidate at clinical scale. This validates SwiftScale’s ability to use its rapid biologics manufacturing technology to accelerate development of treatments for COVID-19.   “SwiftScale has a dedicated focus on manufacturing antibody treatments for COVID-19 and accelerating clinical development timelines,” said David Mace, CEO. “SwiftScale is proud to announce a partnership to manufacture B...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters